Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEZanne first-line ES-SCLC dose-optimization study
2024-517490-24-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Mar 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, open-label trial of turmetabart adizutecan, atezolizumab, carboplatin and etoposide in small cell lung cancer (SCLC) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Progression-free survival. Planned start Mar 2026; status: authorised.
02
Drugs
turmetabart adizutecanatezolizumabcarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-517490-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517490-24-00.